Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Innovate Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Funding
Details : Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 23, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Innovate Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Funding